Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma

Journal: Cancer Medicine

Authors: Tareq M Anssar ¹, Michael F Leitzmann ², Ralf A Linker ¹, Christoph Meier ^3 4 5, Claudia Becker ^3 5, Susan Jick ^4 6, Katharina Sahm ^7 8, Michael Platten ^7 8, Peter Hau ¹, Corinna Seliger ^1 9

NLM Citation: Anssar TM, Leitzmann MF, Linker RA, Meier C, Becker C, Jick S, Sahm K, Platten M, Hau P, Seliger C. Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma. Cancer Med. 2020 Feb;9(3):1263-1275. doi: 10.1002/cam4.2767. Epub 2019 Dec 10. PMID: 31821741; PMCID: PMC6997055.

Abstract

Effectors from the immune system can modulate the course and possibly the early development of gliomas. We, therefore, hypothesized that autoimmune diseases associated with increased immune-surveillance may also modulate the risk of human glioma. To test this hypothesis, we used data from the well-validated Clinical Practice Research Datalink (CPRD) GOLD from the UK to analyze the association of immune-related disorders or use of immunosuppressive drugs and the risk of glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. We randomly selected up to 10 controls, matching them to glioma cases on age, sex, index date, general practice, and number of years of active history in the database prior to the index date. We performed conditional logistic regression analyses to estimate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune diseases, and immunosuppressive drugs. Overall, we found no materially altered association between a history of any autoimmune disease (OR 0.98, 95% CI 0.86-1.11), allergy (OR 0.97, 95% CI 0.89-1.05), or use of immunosuppressive drugs and the risk of glioma. However, subgroup analyses among younger patients found a statistically significant increased risk of glioma in patients with a history of inflammatory bowel disease (IBD) (OR 2.59, 95% CI 1.31-5.12). There was also an inverse association between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% CI 0.58-0.91) and between long-term duration diabetes and risk of glioma (OR 0.71, 95% CI 0.53-0.96).

Keywords: autoimmune diseases; glioma; immunosuppressive therapies.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.